Christian Leisner

Drug developer & biotech entrepreneur

[Christian Leisner @ChrisLeisner]

@TheTNHoller @zannymb @jpmorgan Disappointing to see

[Samuel Hume @DrSamuelBHume]

Top 5 advances in medicine this week (🧵)

1. A drug that beats chemotherapy in a subset of lung cancers

Small cell lung cancer is usually treated with chemotherapy, but resistance is common, and side-effects can be severe

Tarlatamab is a bispecific antibody: it recruits T cells directly to cancer cells - via a protein expressed by ~90% of small cell lung cancers (called DLL3)

Tarlatamab has accelerated approval to treat small cell lung cancer as second line after platinum chemotherapy - this phase 3 trial provides the data to (potentially) upgrade this to full approval

Tarlatamab improved overall survival vs. physician’s choice of chemotherapy, with fewer grade 3 adverse events (though with a new side-effect - cytokine release syndrome)

Ongoing phase 3 trials are testing Tarlatamab as part of first-line combinations

https://t.co/ycsl4dahLn

[Christian Leisner @ChrisLeisner]

@ArtCandee Yeah, right

[CDR-Life @CDRLifeBiotech]

Say hello to Sophie Barsin, our Portfolio Management expert! Her unique perspective complements our scientists' expertise, creating a balanced approach that drives project success and helps guides promising research toward meaningful outcomes.
Learn more https://t.co/XvH2AwhbX9

[CDR-Life @CDRLifeBiotech]

Pipeline Expansion: CDR111, novel trispecific molecule for immune reset in autoimmune diseases! Plus, oncology updates at #AACR25! Join us on April 28 for TCE data:
· CDR404 – Potential best-in-class MAGE-A4 TCE
· Novel TCE for HLA-A*01/KK-LC-1 tumors
https://t.co/QI7JYpOiQt

[CDR-Life @CDRLifeBiotech]

Excited to hold our first Autoimmune Scientific Advisory Board meeting today! With CDR404's clinical progress & our new CDR111 (CD3xCD19xBCMA trispecific) for immune reset, our proprietary antibody-based M-gager® platform expands our unique T cell engager approach to autoimmunity

[Christian Leisner @ChrisLeisner]

Great conversation today with the, as always, well-prepared Brad Loncar.

[BiotechTV @BiotechTV]

From Zurich: CDR-Life is leveraging its antibody expertise to design highly specific T-cell engagers against targets few others are able to pursue.

Full video: https://t.co/3TLk7xQH57

[Christian Leisner @ChrisLeisner]

Now treating cancer patients

[CDR-Life @CDRLifeBiotech]

#NEWS: CDR-Life hits major milestones in cancer immunotherapy!
✅ First patient dosed with CDR404 (MAGE-A4 target)
✅ CDR813 (PRAME target) advances as promising clinical candidate

Our M-gager® tech is pushing boundaries in solid tumor treatment.

https://t.co/o1AvaSM1XB

[Boehringer Ingelheim @Boehringer]

#NEWS: Following Phase I results, we're planning to advance a potential new treatment of Geographic Atrophy. We developed the antibody BI 771716 using technology licensed from @CDRLifeBiotech

Learn more 👉 https://t.co/9sENScXD2P

#RetinalDiseases #ClinicalTrials #VisionHealth

[Christian Leisner @ChrisLeisner]

Ph 1 being key with this approach, proud to see the positive clinical data from @Boehringer with a @CDRLifeBiotech originated molecule

[CDR-Life @CDRLifeBiotech]

#NEWS: With licensed technology developed by CDR-Life, @Boehringer announces positive Phase 1 results for BI 771716, an antibody fragment-based treatment for geographic atrophy, a major cause of vision loss. Learn more 👉https://t.co/ftjtz4yFXI

[Christian Leisner @ChrisLeisner]

@bradloncar Would love to connect in Zurich, Brad

[CDR-Life @CDRLifeBiotech]

Great news! CDR-Life expands its innovative cancer therapy portfolio with the addition of two highly tumor-targeted T cell engagers (TCE): CDR813 and CDR505: Read more:https://t.co/XKCWpMVVUH

[Christian Leisner @ChrisLeisner]

#asco24

[CDR-Life @CDRLifeBiotech]

We are thrilled to annonce the initiation of enrollment for the Phase 1 trial of CDR404, our lead program in development as a precision immunotherapy for solid tumors, published online during #ASCO24. Read more: https://t.co/TdEK7d1MzI

[CDR-Life @CDRLifeBiotech]

CDR-Life has announced that Chief Medical Officer Swethajit Biswas will co-lead a seminar on translational insights into cell engager drugs at the 6th Annual Cell Engager Summit on May 21 in Boston. https://t.co/QuX2IVNWyc

[CDR-Life @CDRLifeBiotech]

Congrats to @Amgen on FDA approval of the second ever T cell Engager therapy in solid tumors. It is so exciting to see great progress being made in the T cell engager space. https://t.co/c06Uy6ejXD

[Christian Leisner @ChrisLeisner]

Proud of the team behind this molecule for #geographicatrophy

[CDR-Life @CDRLifeBiotech]

CDR-Life has announced the advancement of the Phase 1 study with BI 771716 for the treatment of #geographicatrophy: https://t.co/QuX2IVNWyc

[Christian Leisner @ChrisLeisner]

@LeoBorrasLife will be talking about CDR-Life’s leading T cell engager technology.

[CDR-Life @CDRLifeBiotech]

CDR-Life has announced a presentation on its proprietary antibody-MHC technology for the development of highly specific T-cell engagers at the TCR-Based Therapies for Solid Tumors Summit: https://t.co/mdL2vdj1DT

[CDR-Life @CDRLifeBiotech]

CDR-Life has announced a presentation on its proprietary antibody-MHC technology for the development of highly specific T-cell engagers at the TCR-Based Therapies for Solid Tumors Summit: https://t.co/mdL2vdj1DT

[Christian Leisner @ChrisLeisner]

If you are in San Diego at #AACR24, check out our exciting new T cell engager target

[CDR-Life @CDRLifeBiotech]

CDR-Life has announced the presentation of preclinical data demonstrating the promising anti-tumor properties of its peptide MHC T-cell engager antibodies at the #AACR24 Annual Meeting: https://t.co/mdL2vdj1DT

[Christian Leisner @ChrisLeisner]

Thank you @cathshaffer for a great conversation about CDR-Life’s first M-gager IND

[CDR-Life @CDRLifeBiotech]

Check out this great article by @cathshaffer at Precision Medicine Online on how CDR-Life is developing a pipeline of antibody-based T-cell engagers directed to promising cancer targets: https://t.co/qAVwpCXonQ